MyFinsight
Home
Blog
About
Proceeds from the march
2026 public offering...
$81,459,000
Proceeds from exercised
enrollment date and release...
$543,000
Proceeds from exercise of
stock options
$41,884
Net cash provided by
(used in) financing...
$2,363,879
Effect of exchange rate
changes on cash and cash...
$107,271
Canceled cashflow
$79,680,005
Net decrease in cash
and cash...
-$12,253,044
Canceled cashflow
$2,471,150
Stock-based compensation
expense
$7,247,089
Accrued expense and
other current...
$1,829,966
Prepaid expenses and
other current assets
-$1,190,263
Changes in fair value of
warrant liabilities
$1,110,526
Depreciation and
amortization
$813,035
Accounts payable
$674,881
Other non-cash items,
net
-$179,000
Amortization of finance
right-of-use assets
$21,295
Proceeds from sales and
maturities of investments
$9,713,855
Proceeds from the sale of
equipment
$783
something is missing
-$79,599,576
Principal payments on
financed director and...
$76,000
Tax payments for
share settlement of...
$4,429
Net cash used in
operating activities
-$9,840,870
Net cash (used in)
provided by investing...
-$4,883,324
Canceled cashflow
$13,066,055
Canceled cashflow
$9,714,638
Net income (loss)
-$22,491,115
Purchases of investments
$13,012,219
Accrued interest
receivable
$288,720
Operating lease
right-of-use assets and...
$163,776
Purchases of property,
plant and equipment
$1,585,743
Back
Back
Cash Flow
SAB Biotherapeutics, Inc. (SABSW)
SAB Biotherapeutics, Inc. (SABSW)
source: myfinsight.com